Shanghai Haihe Pharmaceutical Co., Ltd and 3SBio Inc. (HKG: 1530), two Chinese pharmaceutical companies, have jointly announced a licensing agreement that grants 3SBio the exclusive rights to commercialize Haihe’s paclitaxel oral solution in mainland China and Hong Kong.
According to the agreement, 3SBio will pay an undisclosed upfront sum along with additional research and development and marketing milestone payments. Haihe Pharmaceutical will retain responsibility for conducting the Phase III clinical trials and all subsequent development, clinical, and regulatory efforts.
The paclitaxel oral solution, originally developed by South Korea-based Daehwa Pharmaceutical using lipid self-emulsification-based drug delivery technology, is the world’s first oral formulation of paclitaxel approved for the second-line treatment of advanced, metastatic, or locally recurrent gastric cancer in South Korea. Haihe licensed the product for development, manufacturing, and marketing rights in China and Thailand. Last month, it received approval in China to treat advanced gastric cancer patients who have experienced disease progression during or after first-line fluorouracil-based regimens.- Flcube.com
